SCHEMBL516174

SCHEMBL516174

COC(=O)c1cccc2c1oc1ccccc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.53
HDAC1 Q13547 1/20 0.52
HDAC8 Q9BY41 1/20 0.52
HDAC6 Q9UBN7 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.49
NPC1 O15118 4/20 0.48
RAB9A P51151 4/20 0.48
ALDH1A1 P00352 4/20 0.48
HPGD P15428 1/20 0.48
LMNA P02545 2/20 0.47
TSHR P16473 1/20 0.47
HSD17B10 Q99714 2/20 0.46
CFTR P13569 1/20 0.46
ATM Q13315 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
MAOA P21397 1/20 0.45
KMT2A Q03164 1/20 0.45
POLB P06746 1/20 0.45
TNKS O95271 1/20 0.45
ALOX5 P09917 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3384509 0.89 KDM4E (0.61) KDM4ESMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL68630 0.88 LMNA (0.50) KDM4EALDH1A1LMNATSHRHSD17B10
SCHEMBL4554338 0.88 ALOX5 (0.50) KDM4EHDAC1HDAC8HDAC6SMN1; SMN2
SCHEMBL20531407 0.86 MAPT (0.52) KDM4EHDAC1HDAC8HDAC6SMN1; SMN2
SCHEMBL18927126 0.83 KDM4E (0.49) KDM4EHDAC1HDAC8HDAC6SMN1; SMN2
SCHEMBL19760841 0.82 KDM4E (0.54) KDM4ESMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL17917512 0.82 KDM4E (0.58) KDM4ESMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL17917511 0.82 KDM4E (0.48) KDM4EHDAC1HDAC8HDAC6SMN1; SMN2
SCHEMBL17917527 0.82 MAPT (0.46) KDM4EHDAC1HDAC8HDAC6SMN1; SMN2
SCHEMBL14825579 0.81 ALOX5 (0.48) KDM4EHDAC1HDAC8HDAC6NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120028968-A1 NOVEL DIBENZOFURANYL-OXADIAZOLYL-DIAZABICYCLONONANE DERIVATIVES AND THEIR MEDICAL USE NEUROSEARCH A/S (DK) 2012-02-02 US disclosed
WO-2010086279-A1 NOVEL DIBENZOFURANYL-OXADIAZOLYL-DIAZABICYCLONONANE DERIVATIVES AND THEIR MEDICAL USE NEUROSEARCH A/S (DK) 2010-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028968-A1 NOVEL DIBENZOFURANYL-OXADIAZOLYL-DIAZABICYCLONONANE DERIVATIVES AND THEIR MEDICAL USE CHRNA10, CHRNA6, CHRNA7 KDM4E 2635/4885HDAC1 2099/4885HDAC8 2677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.